Northrop Grumman/$NOC

1D1W1MYTD1Y5YMAX

About Northrop Grumman

Northrop Grumman is a diversified defense contractor providing aeronautics, defense, and space systems. The company's aerospace segment produces autonomous and piloted aircraft such as Global Hawk drones and the new B-21 bomber, creates the fuselage for the massive F-35 program, and maintains and upgrades numerous other military aircraft. Defense systems makes artillery and missile ammunition and guidance systems, long-range missiles, and missile defense systems. Mission systems creates and integrates a variety of radar, navigation, and communication systems for avionics, weapons control, and countermeasures on a range of platforms from helicopters to destroyers. Space systems produces satellites, sensors, space structures, and rocket motors.
Ticker
$NOC
Primary listing
NYSE
Employees
95,000

Northrop Grumman Metrics

BasicAdvanced
$75B
16.87
$31.50
-0.10
$9.40
1.86%

What the Analysts think about Northrop Grumman

Analyst ratings (Buy, Hold, Sell) for Northrop Grumman stock.
Analyst projections of the future price of Northrop Grumman stock.

Bulls say / Bears say

Northrop Grumman lifted its 2026 revenue forecast by $250 million to a range of $43.75–$44.25 billion and raised adjusted profit guidance, supported by sustained weapons demand, as its total backlog climbed 9% to $104.7 billion (Reuters via Investing.com).
The company delivered adjusted Q2 earnings per share of $7.68, topping the $6.82 consensus, while revenue of $10.9 billion slightly exceeded forecasts, marking its fourth consecutive quarter of earnings beats (Reuters via Investing.com).
Aeronautics Systems sales rose 13% year-over-year to $3.5 billion, driven by higher volumes on the B-21 Raider program and mature production on the E-130J TACAMO, bolstering segment profitability (Reuters via Investing.com).
Northrop Grumman’s Q2 net earnings declined 7% year-over-year to $1.09 billion, primarily due to a $329 million drop in operating income despite revenue growth (SEC).
The Defense Systems segment operating income plunged 38% to $156 million in Q2, reflecting margin compression and a $68 million unfavorable EAC adjustment on the Stand-in Attack Weapon program (SEC).
Northrop Grumman’s shares fell in pre-market trading after the Q2 release as investors weighed escalating program costs and rising capital expenditures, highlighting concerns over cash flow sustainability (Reuters via Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.

Northrop Grumman Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Northrop Grumman Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Northrop Grumman

AllEURGBPUSD
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.